Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency

Torres, Carolina Machado; Netto, Cristina Brinckmann Oliveira; Vedolin, Leonardo; Garzón, Eliana; Rieder, Carlos Roberto de Mello; Schwartz, Ida Vanessa Döederlein; Bianchin, Marino Muxfeldt

doi:10.1590/s0004-282x2011000400031

Cited by 9 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Electrographic or electro-clinical seizures frequently recur during weaning of pharmacologic coma medications [ 97 , 98 , 99 , 100 ], indicating that pharmacologic coma should be considered as a window during which specific therapies can be instituted for some status epilepticus etiologies and during which other anti-seizure medications can be initiated to provide additional coverage. Only case reports and series are available to guide management at this stage, and the options include topiramate [ 101 , 102 , 103 , 104 , 105 , 106 , 107 ], lacosamide [ 108 , 109 , 110 ], phenobarbital [ 111 , 112 , 113 , 114 ], ketamine [ 115 , 116 , 117 , 118 , 119 ], pyridoxine [ 120 , 121 , 122 , 123 , 124 , 125 ], neurosteroids [ 126 ], lidocaine [ 127 , 128 , 129 ], the ketogenic diet [ 90 , 102 , 130 , 131 , 132 , 133 , 134 , 135 , 136 ], therapeutic hypothermia [ 137 , 138 , 139 , 140 , 141 ], immunomodulation [ 142 , 143 ], epilepsy surgery [ 115 , …”

Section: Management Of Refractory Status Epilepticusmentioning

confidence: 99%

Management of Status Epilepticus in Children

Smith

McGinnis

Walleigh

et al. 2016

JCM

View full text Add to dashboard Cite

Status epilepticus is a common pediatric neurological emergency. Management includes prompt administration of appropriately selected anti-seizure medications, identification and treatment of seizure precipitant(s), as well as identification and management of associated systemic complications. This review discusses the definitions, classification, epidemiology and management of status epilepticus and refractory status epilepticus in children.

show abstract

Section: Management Of Refractory Status Epilepticusmentioning

confidence: 99%

Management of Status Epilepticus in Children

Smith

McGinnis

Walleigh

et al. 2016

JCM

View full text Add to dashboard Cite

show abstract

“…TPM is not approved for use in SE. To date, there are 15 case reports and series with a total of 268 pediatric and adult subjects with RSE/SRSE and a responder rate of 17-100% [100][101][102][103][104][105][106][107][108][109][110][111][112][113][114]. AEs (predominantly hyperammonemia) in seven reports (47%), with a frequency of between 0 and 36%, were reported, mostly during the simultaneous intake of VPA [100, 102, 105-107, 111, 114].…”

Section: Antiseizure Drugs (Asds)mentioning

confidence: 99%

Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Background Refractory status epilepticus (RSE) represents a serious medical condition requiring early and targeted therapy. Given the increasing number of elderly or multimorbid patients with a limitation of life-sustaining therapy (LOT) or within a palliative care setting (PCS), guidelines-oriented therapy escalation options for RSE have to be omitted frequently. Objectives This systematic review sought to summarize the evidence for fourth-line antiseizure drugs (ASDs) and other minimally or non-invasive therapeutic options beyond guideline recommendations in patients with RSE to elaborate on possible treatment options for patients undergoing LOT or in a PCS. Methods A systematic review of the literature in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, focusing on fourth-line ASDs or other minimally or non-invasive therapeutic options was performed in February and June 2020 using the MEDLINE, EMBASE and Cochrane databases. The search terminology was constructed using the name of the specific ASD or therapy option and the term 'status epilepticus' with the use of Boolean operators, e.g. "(brivaracetam) AND (status epilepticus)". The respective Medical Subject Headings (MeSH) and Emtree terms were used, if available. ResultsThere is currently no level 1, grade A evidence for the use of ASDs in RSE. The best evidence was found for the use of lacosamide and topiramate (level 3, grade C), followed by brivaracetam, perampanel (each level 4, grade D) and stiripentol, oxcarbazepine and zonisamide (each level 5, grade D). Regarding non-medicinal options, there is little evidence for the use of the ketogenic diet (level 4, grade D) and magnesium sulfate (level 5, grade D) in RSE. The broad use of immunomodulatory or immunosuppressive treatment options in the absence of a presumed autoimmune etiology cannot be recommended; however, if an autoimmune etiology is assumed, steroid pulse, intravenous immunoglobulins and plasma exchange/plasmapheresis should be considered (level 4, grade D). Even if several studies suggested that the use of neurosteroids (level 5, grade D) is beneficial in RSE, the current data situation indicates that there is formal evidence against it. Conclusions RSE in patients undergoing LOT or in a PCS represents a challenge for modern clinicians and epileptologists. The evidence for the use of ASDs in RSE beyond that in current guidelines is low, but several effective and well-tolerated options are available that should be considered in this patient population. More so than in any other population, advance care planning, advance directives, and medical ethical aspects have to be considered carefully before and during therapy.

show abstract

“…Its enteral and oral formulations are currently available. A few case reports in adults [99][100][101] and children [102][103][104][105][106][107][108], as well as case series [109,110], have reported on topiramate as an add-on treatment for SE and RSE.…”

Section: Topiramatementioning

confidence: 99%

Combination drug therapy for the treatment of status epilepticus

Wang¹,

Jin

Chen

2015

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Status epilepticus (SE) is a common neurological emergent disease with high mortality and disability rates. Rapidly and effectively controlling seizures is key to saving the lives of patients and improving their prognoses. Traditional antiepileptic drugs for SE are ineffective in 30-40% of cases. In light of the diverse etiology and complex pathogenesis of SE, combination drug therapy for SE might be more conducive for the treatment of all patients because the combined use of drugs can produce synergistic effects via different mechanisms. This review summarizes combination drug therapies used for SE in animal experiments and clinical practice, the potential advantages of combination drug therapy and specific combination drug therapies using different antiepileptic drugs. The aim is to help researchers seek better treatments for early termination of SE.

show abstract

Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency

Cited by 9 publications

References 3 publications

Management of Status Epilepticus in Children

Management of Status Epilepticus in Children

Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review

Combination drug therapy for the treatment of status epilepticus

Contact Info

Product

Resources

About